这些被质疑的论文所涉及的学术不端，主要是一图多用，图片PS等。目前仅有少数几篇被质疑论文得到作者回应，作者回应称“论文中无意的错误并不影响实验结论”。 截至2024年9月5日，Gregg L.

The RESILIENCE clinical trial has been designed to explore the effectiveness and safety of remote ischemic conditioning (RIC) ...

Considering taking supplements to treat anthracycline cardiotoxicity? Below is a list of common natural remedies used to treat or reduce the symptoms of anthracycline cardiotoxicity. Follow the ...

Management. Salvage chemotherapy regimens including bortezomib plus steroid, alkylators plus steroid, bortezomib plus anthracycline and radiotherapy, and combined bortezomib, cyclophosphamide ...

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less ...

当以相同剂量给药时，我们无法偏向表柔比星或阿霉素。根据目前关于心力衰竭的证据，我们得出结论，对于患有实体瘤的成年人，脂质体包裹的阿霉素应该比阿霉素更受青睐。对于表柔比星与阿霉素以及脂质体包裹的阿霉素与传统阿霉素的比较，无法得出关于 ...

During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

Southwest Research Institute (SwRI) is collaborating with The University of Texas at San Antonio (UTSA) to explore and ...

Chemotherapy is generally administered before hormone therapy in patients with endocrine-responsive breast cancer, but there is a paucity of data to indicate that long-term outcomes are better ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

ASX health stocks have fallen this week but Morgans analyst Scott Power is more optimistic after the Fed cut the cash rate by ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.